Business
Omnicell Announces First Quarter 2025 Results
Omnicell delivers solid first quarter financial results Results exceed previously issued first quarter 2025 guidance for total revenues and non-GAAP EPS
About this update from Omnicell, Inc.
[{"type":"text","content":"\nOmnicell delivers solid first quarter financial results\n\nResults exceed previously issued first quarter 2025 guidance for total revenues and non-GAAP EPS\n\nUpdates full year 2025 non-GAAP EBITDA and non-GAAP EPS guidance\n\n FORT WORTH, Texas--(BUSINESS WIRE)--\nOmnicell, Inc. (NASDAQ:OMCL) (“Omnicell,” “we,” “our,” “us,” “management,” or the “Company”), a leader in transforming the pharmacy and nursing care delivery model, today announced results for its first quarter ended March 31, 2025.\n\n“We delivered strong financial results for the first quarter of 2025, exceeding our previously provided guidance ranges for both revenue and earnings, which we believe reflects customers embracing the industry-defined vision of the Autonomous Pharmacy including medication management solutions across the continuum of care,” stated Randall Lipps, chairman, president, chief executive officer, and founder of Omnicell. “While uncertainty surrounding the potential impact of tariffs has compelled us to update our full-year outlook, our focus on driving annual recurring revenue services and recurring revenue is expected to serve us well as we implement strategies that are designed to mitigate the potential impact of tariffs on our supply chain. Importantly, our balance sheet remains strong, with solid free cash flow, which should help us remain nimble and capable of navigating the current macroeconomic environment while continuing to offer market-leading innovation and execution that our customers have come to expect.”\n\nFinancial Results\n\nTotal revenues for the first quarter of 2025 were $270 million, up $24 million, or 10%, from the first quarter of 2024. The year-over-year increase in total revenues is primarily due to the increase in revenues from our XT Amplify program, as well as continued growth in our SaaS and Expert Services, including an increase in revenues from our Specialty Pharmacy Services offering.\n\nTotal GAAP net loss for the first quarter of 2025 was $7 million, or $0.15 per diluted share. This compares to GAAP net loss of $16 million, or $0.34 per diluted share, for the first quarter of 2024.\n\nTotal non-GAAP net income for the first quarter of 2025 was $12 million, or $0.26 per diluted share. This compares to non-GAAP net income of $1 million, or $0.03 per diluted share, for the first quarter of 2024.\n\nTotal non-GA...